The focus of this study was to characterize a novel biomarker for cystic fibrosis (CF) that could reflect exacerbations of the disease and could be useful for therapeutic stratification of patients, or for testing of potential drug treatments. This study focused exclusively on a protein complex containing alpha-1 antitrypsin and CD16b (AAT:CD16b) which is released into the bloodstream from membranes of proinflammatory primed neutrophils.
Introduction
Cystic fibrosis is an autosomal recessive condition and although a multi-organ disorder, end-stage lung disease with chronic bacterial infection is the major cause of morbidity and mortality in affected individuals (1) . The pathogenesis of lung disease induced by CF is a direct result of decreased chloride secretion and hyper-absorption of sodium, resulting in the retention of dehydrated mucus within the airways (2) . This thickened mucus provides an ideal environment for bacterial infection in the respiratory tract. Staphylococcus aureus (S. aureus) is the major bacterial pathogen in early years but subsequently Pseudomonas aeruginosa (P. aeruginosa) becomes the prominent pathogen in adult patients (3, 4) . Adding to this lung microbiome in CF, obligate anaerobes in CF sputum samples including Prevotella, S. saccharolyticus, Peptostreptococcus prevotii and Actinomyces have been detected (5, 6) . Intravenous (i.v.) antibiotics are normally used for acute infective exacerbations with efficacy assessed by monitoring respiratory function, body weight and circulating markers of systemic inflammation (7) .
In addition to ineffective mucociliary and cough clearance, persistent expression of inflammatory cytokines and chemokines plays a major role in the pathogenesis of chronic lung disease (8) , leading to recruitment and activation of neutrophils in the CF airways (9) . Longitudinal and prospective studies of infants with CF and also within an animal model with mutated CFTR genes, demonstrates that airway inflammation follows respiratory infection (10) . Thus an increasing volume of clinical data supports the use of early antimicrobial treatment to inhibit (11) or delay (12) bacterial infection and to achieve decreased hospitalization and improved patient survival. For this reason there has been increased interest in the use of infective exacerbations (frequency and resolution) as an outcome measure in clinical trials and sensitivity to treatment. However, whilst there are a number of criteria put forward to define an exacerbation (13) (14) (15) (16) variability among parameters exists (17) . Moreover, as new agents are investigated in clinical trials and new therapeutic targets are identified, it is becoming increasingly important to accurately define the clinical signs and symptoms of pulmonary exacerbations and to define objective markers of infection (18) .
Inflammatory biomarkers represent a solution to the variation in the clinical criteria defining exacerbations in CF. Thus far identified biomarkers indicative of increased pulmonary inflammation with P. aeruginosa infection include serum levels of G-CSF (19) and matrix metalloproteinase-1, -8 and -9 (20) . Alternatively levels of cytokines including IL-8 (21) , neutrophil released elastase (22) , myeloperoxidase (23) and cathepsin B and S (24) have been evaluated as markers of pulmonary exacerbation in sputum samples. However, one aspect of neutrophil physiology which has largely been overlooked is pre-activation or priming of the circulating cell. Neutrophil priming is a prerequisite for homing to the lung and can be used as read-out for the in vivo action of pro-and anti-inflammatory cytokines. Consequently, we hypothesized that markers of neutrophil priming in the systemic compartment would serve as an early read-out for pulmonary exacerbation in CF and should be normalized upon optimal treatment.
Recently we have shown that the acute phase protein alpha-1 antitrypsin, is bound to the circulating neutrophil via interaction with the glycosylphosphatidyl-inositol (GPI) linked membrane protein CD16b (FcRIIIb) (25) . Moreover, soluble immune complex (sIC) primed the circulating neutrophil to release AAT from the cell membrane within a protein complex with CD16b. Within the present study we investigated the potential of neutrophil released AAT:CD16b protein complex to serve as a potential marker of infective inflammation and resolution of pulmonary exacerbation in adult patients with CF. Some of the results of this study have been previously reported in the form of an abstract (26).
Materials and methods

Chemicals and reagents
All chemicals and reagents were endotoxin free and were purchased from Sigma-Aldrich unless indicated otherwise.
Patient groups
Four patient groups and healthy control volunteers were recruited to this study as follows: 1: Asymptomatic alpha-1 antitrypsin deficient individuals (AATD) not receiving therapy were recruited from the Irish Alpha-1 Antitrypsin Deficiency Registry (n=10, mean age 43.95 ± 8.53). AATD patients had plasma AAT levels <11 M and were clinically stable with a forced expiratory volume in one second (FEV1) of 98.2% ± 17.48% predicted. 2: Adult patients with COPD (n=10) and a history of smoking were recruited as previously described (27) ). An exacerbation was defined by previously validated criteria (28) . 4: All non-CF bronchiectasis patients (n= 6, mean age 64 ± 6.7, mean % FEV1 of 59% predicted) were recruited from a specialized non-CF bronchiectasis clinic and had no evidence of an exacerbation at the time of recruitment. 5: Control volunteers (n=14, mean age 34.72 ± 3.17) had no respiratory symptoms and were not on medication. All participants gave written informed consent to participate in the study, which was approved by Beaumont Hospital Ethics Committee.
Neutrophil isolation and membrane fractionation.
Neutrophils were purified from whole blood and membranes were isolated as previously described employing sucrose density ultracentrifugation (25) . The methodology for flow cytometry, proteomic analysis, SDS-PAGE and Western blotting of neutrophil plasma membranes can be found within the supplemental materials and methods.
Enzyme linked immunosorbent assays (ELISAs)
The concentration of IL-8 or TNF-alpha in plasma samples was measured by enzyme linked immunosorbent assay (ELISA), conducted in accordance with the manufacturer's instructions (R&D Systems). For the detection of AAT:CD16b complex within plasma samples of healthy control, AATD or patients with CF, 5g/ml of specific mouse anti-CD16b (R&D systems) was employed as a capture antibody and 50ng/ml of polyclonal goat anti-AAT specific antibody (Abcam) as a detection antibody, followed by an anti-goat IgG conjugated to HRP. Prior to each assay, wells from Nunc 96-well microtiter plates were coated with capture antibody suspended in Buffer A (15 mM Na 2 CO 3 and 35 mM NaHCO 3 , pH 9.3) over night at 4°C. The wells were subsequently washed in Buffer A, blocked with bovine serum albumin (BSA; 1% w/v) for 1h and exposed to patient plasma (100l). As the ELISA was based on quantification of AAT complexed to CD16b that is captured by the anti-CD16b antibody, serial dilutions of purified human AAT was simultaneously coated in triplicate in the Nunc 96-well microtiter plate to establish a standard curve as previously described (29) . Controls included all reagents except capture, detection antibody or biotinylated secondary antibody.
Statistical analysis
All experiments were performed a minimum of three times and results expressed as means ± standard error of the mean. The data was analyzed with the GraphPad Prism version 4.03 for Windows (GraphPad Software, USA). Continuous data were tested for normality (1 sample Kolmogorov -Smirnoff test) and where normal were compared using an unpaired student t-test. Differences were considered significant at P ≤ 0.05.
Quantification of protein abundance was determined using the biological variation analysis module of Decyder™ using ANOVA-1 analysis for comparing across the different groups (healthy controls, non-CF bronchiectasis and CF samples pre-and postantibiotic treatment). Differential expression was defined as greater than 1.5-fold change in expression with a P-value ≤ 0.05.
Results
Proinflammatory mediators cause release of AAT and CD16b from neutrophil membranes.
We have previously shown that exposure of neutrophils to sIC causes release of AAT and CD16b from the neutrophil membrane in a complex form (25) . To build on this background information the effect of the proinflammatory stimulus IL-8, on release/shedding of AAT and CD16b from the neutrophil membrane was investigated.
Neutrophils were primed with IL-8 (10ng/2x10 7 cells) and after 10 min of treatment a significant decrease in cell surface AAT was detected by flow cytometry (control untreated mean fluorescence = 50.98 ± 0.67 and IL-8 treated cells mean = 17.62 ± 0.06, P<0.05) ( Fig. 1A) . Moreover, the observed decrease in membrane AAT corresponded with a reduction in CD16b expression (control untreated mean fluorescence = 38.75 ± 0.11 and IL-8 treated cells mean = 19.22 ± 0.05, P<0.05) ( Fig. 1B ). Furthermore, we have previously shown that release of AAT:CD16b complex from the cell membrane in response to sIC involves surface sheddase activity including ADAM-17 (25) . We therefore investigated whether ADAM-17 activity was required for concomitant release of AAT with CD16b in response to TNF-alpha. This was confirmed when cells were primed with TNF-alpha (10ng/2x10 7 cells) and the extracellular supernatants analysed by Western blot for the presence of released CD16b and AAT (Fig. 1C ). TNF-alpha induced release of CD16b and AAT at 5 and 10 min post exposure, an effect inhibited by inclusion of the specific ADAM-17 inhibitor, TAPI-1 (10 M) (30). TAPI-1 prevented release of AAT and CD16b in response to TNF-alpha and significantly reduced the extracellular detectable level of the two proteins by approximately 80% at the 5 min time point (P<0.05) ( Fig. 1D ). Collectively, these results demonstrate that neutrophils primed by pro-inflammatory mediators including IL-8 and TNF-alpha, rapidly release AAT and CD16b from the neutrophil membrane.
Increased levels of proinflammatory mediators and CD16b:AAT complex in plasma from CF patients.
Quantification of IL-8 by ELISA revealed significantly elevated levels of IL-8 in CF plasma compared to COPD and control subjects (553.8 ± 82.2 versus 249.9 ± 26.2 and 168.3 ± 51.2 pg/ml plasma respectively, P<0.05) ( Fig. 2A ). In accordance with results obtained for IL-8, significantly elevated levels of TNF-alpha were measured in CF plasma compared to COPD and control subjects (10.43 ± 2.12 versus 1.56 ± 0.75 and 4.16 ± 1.02 pg/ml plasma respectively, P<0.05) ( Fig. 2B ). Moreover, individuals with CF were more likely to have elevated plasma levels of AAT:CD16b compared to COPD and control groups (Fig. 2C ). Significantly higher levels of AAT:CD16b protein complex were detected in CF patient plasma (6.47 ± 0.65 ng/ml) compared with results from the other groups (COPD = 0.73 ± 0.26, AATD = 0.01 ± 0.005 and control = 0.80 ± 0.24; concentration of AAT:CD16b complex (n = 62, r = 0.4223; P = 0.0001; Fig. 3 ). Taken together these results illustrate a novel correlation between increased pro-inflammatory mediators and AAT:CD16b complex plasma levels.
Levels of AAT:CD16b complex in CF patients decrease post antibiotic therapy.
To determine if levels of AAT:CD16b complex in plasma could reflect the inflammatory states of individuals with CF, we carried out analysis of patients plasma pre-and post-antibiotic therapy. Patients were treated for an acute microbial exacerbation related to Pseudomonas aeruginosa (P. aeruginosa) and/or Staphylococcus aureus (S. aureus) bacterial infection predominately. As illustrated in Table 1 , an improvement in spirometry measurements was observed in most cases following treatment (pretreatment CF plasma samples before and after intravenous antibiotic therapy were quantified for AAT:CD16b complex by ELISA. Of the 10 patient samples analyzed, levels of AAT:CD16b decreased after the administration of antibiotic therapy with the exception of 2 (Fig. 4A) . These latter two patients were deemed nonresponsive to treatment and clinical symptoms did not improve with therapy, as measured by a decreased increment in FEV1 (Table 1: the membrane protein spots on the gels from day 0 with that of 14-day post treatment and control membranes, 36 spots showed differential expression. Two of these spots were down-regulated in CF samples on day 0, while they were increased at least 1.5-fold in both the membrane samples from the 14-day-treated CF patients and the samples from Collectively these results indicate that treatment of an exacerbation with antibiotic therapy in CF results in decreasing levels of plasma AAT:CD16b, with a corresponding increase in the level of membrane bound complex and improved FEV1.
Discussion
Pulmonary exacerbations are important contributors to morbidity and are associated with lung function decline over 1 year in CF (31) Research within this area has identified a number of possible biomarkers of CF exacerbation. For example, by employing a proteomic approach of induced sputum from adult patients with CF, proteolytic degradation and glycosylation of mucins MUC5B and MUC5AC (32) or degradation of IgG and alpha-1 antitrypsin, were proposed as predictors of CF lung exacerbation (23) . By immunometric techniques sputum levels of IL-8 have also been shown to significantly alter following treatment of CF exacerbations with antibiotic therapy, suggestive of a noninvasive outcome measure to assess response to therapy in CF patients (33) . However, Downey et al (2007) did not find a reduction in sputum IL-8 levels (7) , indicating that sputum IL-8 correlates poorly with lung function, thus questioning the suitability of IL-8 as a reliable biomarker of CF exacerbations.
Therefore as an alternative to using sputum, serum samples from patients with CF have also been compared with control sera in order to recognize protein expression profiles specific to CF during an exacerbation. Compared to healthy controls, matrix metalloproteinase (MMP-1, -8 and -9 ) and G-CSF serum levels were elevated in adult patients with CF and correlated with pulmonary exacerbation and antibiotic treatment (19, 20) . Serum levels of S100A12 (34), S100A8/A9, CRP and vascular endothelial growth factor (35) have also been suggested as serum markers of acute infectious exacerbations and to decrease significantly post treatment of an exacerbation. Moreover, whilst CF exacerbations were not shown to modulate neutrophil function (36) , neutrophil derived proteins including myeloperoxidase in peripheral blood appeared to reflect inflammatory changes post antibiotic treatment (37) . Myeloperoxidase however is a component of neutrophil primary / azurophilic granules and peroxidase exocytosis is a tightly regulated process. Within the present study, rather than identifying markers of neutrophil activation we have focused on a plasma marker of neutrophil pre-activation or priming. Priming can be induced by pro-inflammatory stimuli which are increased in an in vivo state of CF exacerbation and which prepare the neutrophil for a state of readiness preceding complete activation. The fundamental mechanism leading to a primed response involves increased levels of cytosolic calcium (38) , upregulated tyrosine phosphorylation (39) and cytoskeletal rearrangements (40) . Pseudomonas alginate (41), TNF-alpha and IL-8 have been shown to be important priming agents for CF neutrophils (42) . Recently we have shown that AAT is localized to the neutrophil plasma membrane within lipid rafts bound to CD16b (FcRIIIb) and is released in complex form (AAT:CD16b) by priming with sIC (25) . CD16b is unique in that it is the only Fc receptor linked to the plasma membrane by a GPI anchor and the metalloprotease ADAM-17 has been implicated in the shedding of CD16b. Within the present study we show that priming of neutrophils in vitro with IL-8 and TNF-alpha causes release of CD16b and AAT to the extracellular milieu and in vivo, AAT:CD16b complex plasma levels correlate strongly with these pro-inflammatory mediators. These observations illustrate that the expression of neutrophil priming-associated biomarkers in peripheral blood can be used as read out for the inflammatory process in CF. The AAT:CD16b biomarker may be of benefit to clinical trials determining if drugsin-process are effective against inflammation and may also become an extremely useful addition to the clinical diagnosis of exacerbations and management of CF. analysis and quantification of protein abundance was as previously described using the biological variation analysis module (BVA) of DeCyder TM (32) . Protein identification by LC-MS/MS was performed on an Ultimate 3000 nanoLC system (Dionex), interfaced to an LTQ Orbitrap XL (Thermo Fisher Scientific) as previously described (30) . Database searches were performed using TurboSEQUEST software (Bioworks Browser version 3.3.1) (Thermo Fisher Scientific). The following filters were applied: for charge state 1, X Corr >1.5; for charge state 2, X Corr >2.0; for charge state 3, X Corr >2.5.
